Loading…
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK mo...
Saved in:
Published in: | Journal of pharmacokinetics and pharmacodynamics 2001-12, Vol.28 (6), p.507-532 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03 |
---|---|
cites | |
container_end_page | 532 |
container_issue | 6 |
container_start_page | 507 |
container_title | Journal of pharmacokinetics and pharmacodynamics |
container_volume | 28 |
creator | MAGER, Donald E JUSKO, William J |
description | Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs. |
doi_str_mv | 10.1023/a:1014414520282 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71316403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157705481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03</originalsourceid><addsrcrecordid>eNpd0E1LxDAQBuAgiruunr1JEfRWzVeT1pssugoLHlTwVtJkupu1bWrSgv57o64IHoaZw8PwziB0TPAFwZRdqiuCCeeEZxTTnO6gKckkS3PJ-e7XLGQa62WCDkLYYExEdPtoQkhRFLTAU_S4gA68apJ-rXyrtHu1HQxWJ60z0CS184nx4yok8L62lR1st0oG5VcwpC0YqwYw3yAxNvQuROC6Q7RXqybA0bbP0PPtzdP8Ll0-LO7n18tUc0qHVBhFTa5jDsYZz1XOlIQiMzhjRmohdQaVyaAAVrBcQ025UAXlklQUCNWYzdD5z97eu7cRwlC2NmhoGtWBG0MpCSOCYxbh6T-4caPvYrZSZhIzKQmJ6GSLxiqeVvbetsp_lL-_iuBsC1TQqqm96rQNf44JKlies0_ShHha</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>757037711</pqid></control><display><type>article</type><title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</title><source>Springer Nature</source><creator>MAGER, Donald E ; JUSKO, William J</creator><creatorcontrib>MAGER, Donald E ; JUSKO, William J</creatorcontrib><description>Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.</description><identifier>ISSN: 1567-567X</identifier><identifier>EISSN: 1573-8744</identifier><identifier>DOI: 10.1023/a:1014414520282</identifier><identifier>PMID: 11999290</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Biological and medical sciences ; Dose-Response Relationship, Drug ; Drug Delivery Systems - methods ; Drug Delivery Systems - statistics & numerical data ; Drug Evaluation, Preclinical - methods ; Drug Evaluation, Preclinical - statistics & numerical data ; Drug therapy ; Fluorenes - blood ; Fluorenes - pharmacokinetics ; General pharmacology ; Humans ; Hydantoins - blood ; Hydantoins - pharmacokinetics ; Interferon-beta - blood ; Interferon-beta - pharmacokinetics ; Male ; Medical sciences ; Models, Chemical ; Nonlinear Dynamics ; Pharmacokinetics ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Sulfonamides - blood ; Sulfonamides - pharmacokinetics</subject><ispartof>Journal of pharmacokinetics and pharmacodynamics, 2001-12, Vol.28 (6), p.507-532</ispartof><rights>2002 INIST-CNRS</rights><rights>Plenum Publishing Corporation 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13626388$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11999290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAGER, Donald E</creatorcontrib><creatorcontrib>JUSKO, William J</creatorcontrib><title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</title><title>Journal of pharmacokinetics and pharmacodynamics</title><addtitle>J Pharmacokinet Pharmacodyn</addtitle><description>Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.</description><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Delivery Systems - statistics & numerical data</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Drug Evaluation, Preclinical - statistics & numerical data</subject><subject>Drug therapy</subject><subject>Fluorenes - blood</subject><subject>Fluorenes - pharmacokinetics</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Hydantoins - blood</subject><subject>Hydantoins - pharmacokinetics</subject><subject>Interferon-beta - blood</subject><subject>Interferon-beta - pharmacokinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Models, Chemical</subject><subject>Nonlinear Dynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Sulfonamides - blood</subject><subject>Sulfonamides - pharmacokinetics</subject><issn>1567-567X</issn><issn>1573-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpd0E1LxDAQBuAgiruunr1JEfRWzVeT1pssugoLHlTwVtJkupu1bWrSgv57o64IHoaZw8PwziB0TPAFwZRdqiuCCeeEZxTTnO6gKckkS3PJ-e7XLGQa62WCDkLYYExEdPtoQkhRFLTAU_S4gA68apJ-rXyrtHu1HQxWJ60z0CS184nx4yok8L62lR1st0oG5VcwpC0YqwYw3yAxNvQuROC6Q7RXqybA0bbP0PPtzdP8Ll0-LO7n18tUc0qHVBhFTa5jDsYZz1XOlIQiMzhjRmohdQaVyaAAVrBcQ025UAXlklQUCNWYzdD5z97eu7cRwlC2NmhoGtWBG0MpCSOCYxbh6T-4caPvYrZSZhIzKQmJ6GSLxiqeVvbetsp_lL-_iuBsC1TQqqm96rQNf44JKlies0_ShHha</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>MAGER, Donald E</creator><creator>JUSKO, William J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20011201</creationdate><title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</title><author>MAGER, Donald E ; JUSKO, William J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Delivery Systems - statistics & numerical data</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Drug Evaluation, Preclinical - statistics & numerical data</topic><topic>Drug therapy</topic><topic>Fluorenes - blood</topic><topic>Fluorenes - pharmacokinetics</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Hydantoins - blood</topic><topic>Hydantoins - pharmacokinetics</topic><topic>Interferon-beta - blood</topic><topic>Interferon-beta - pharmacokinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Models, Chemical</topic><topic>Nonlinear Dynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Sulfonamides - blood</topic><topic>Sulfonamides - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAGER, Donald E</creatorcontrib><creatorcontrib>JUSKO, William J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAGER, Donald E</au><au>JUSKO, William J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</atitle><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>28</volume><issue>6</issue><spage>507</spage><epage>532</epage><pages>507-532</pages><issn>1567-567X</issn><eissn>1573-8744</eissn><abstract>Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>11999290</pmid><doi>10.1023/a:1014414520282</doi><tpages>26</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-567X |
ispartof | Journal of pharmacokinetics and pharmacodynamics, 2001-12, Vol.28 (6), p.507-532 |
issn | 1567-567X 1573-8744 |
language | eng |
recordid | cdi_proquest_miscellaneous_71316403 |
source | Springer Nature |
subjects | Biological and medical sciences Dose-Response Relationship, Drug Drug Delivery Systems - methods Drug Delivery Systems - statistics & numerical data Drug Evaluation, Preclinical - methods Drug Evaluation, Preclinical - statistics & numerical data Drug therapy Fluorenes - blood Fluorenes - pharmacokinetics General pharmacology Humans Hydantoins - blood Hydantoins - pharmacokinetics Interferon-beta - blood Interferon-beta - pharmacokinetics Male Medical sciences Models, Chemical Nonlinear Dynamics Pharmacokinetics Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Sulfonamides - blood Sulfonamides - pharmacokinetics |
title | General pharmacokinetic model for drugs exhibiting target-mediated drug disposition |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A52%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=General%20pharmacokinetic%20model%20for%20drugs%20exhibiting%20target-mediated%20drug%20disposition&rft.jtitle=Journal%20of%20pharmacokinetics%20and%20pharmacodynamics&rft.au=MAGER,%20Donald%20E&rft.date=2001-12-01&rft.volume=28&rft.issue=6&rft.spage=507&rft.epage=532&rft.pages=507-532&rft.issn=1567-567X&rft.eissn=1573-8744&rft_id=info:doi/10.1023/a:1014414520282&rft_dat=%3Cproquest_pubme%3E2157705481%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-6da2d8c92934348a83a7e95d053d7c67c5ebd5e9e3938cef246a92471b2e12c03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=757037711&rft_id=info:pmid/11999290&rfr_iscdi=true |